415 related articles for article (PubMed ID: 25189722)
1. Assessing disease burden in patients with classic MPNs.
Geyer H; Mesa RA
Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
[TBL] [Abstract][Full Text] [Related]
2. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.
Ianotto JC; Curto-Garcia N; Lauermanova M; Radia D; Kiladjian JJ; Harrison CN
Haematologica; 2019 Aug; 104(8):1580-1588. PubMed ID: 30679326
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Passamonti F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
[TBL] [Abstract][Full Text] [Related]
5. Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
Sankar K; Stein BL
J Natl Compr Canc Netw; 2018 Dec; 16(12):1539-1545. PubMed ID: 30545998
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutics in myeloproliferative neoplasms.
Venugopal S; Mascarenhas J
J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
[TBL] [Abstract][Full Text] [Related]
7. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
8. Management of symptoms in polycythemia vera and essential thrombocythemia patients.
Radia D; Geyer HL
Hematology Am Soc Hematol Educ Program; 2015; 2015():340-8. PubMed ID: 26637741
[TBL] [Abstract][Full Text] [Related]
9. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.
Geyer HL; Dueck AC; Scherber RM; Mesa RA
Mediators Inflamm; 2015; 2015():284706. PubMed ID: 26538823
[TBL] [Abstract][Full Text] [Related]
10. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
11. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
[TBL] [Abstract][Full Text] [Related]
12. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
Mesa RA; Passamonti F
Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
[TBL] [Abstract][Full Text] [Related]
13. [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients].
Xu J; Xu Z; Wang J; Li B; Sun X; Qin T; Zhang Y; Zhang H; Fang L; Pan L; Hu N; Qu S; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):26-9. PubMed ID: 26876249
[TBL] [Abstract][Full Text] [Related]
14. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
15. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
16. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
17. Emerging treatments for classical myeloproliferative neoplasms.
Vannucchi AM; Harrison CN
Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
[TBL] [Abstract][Full Text] [Related]
18. New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.
Patel AB; Vellore NA; Deininger MW
Clin Cancer Res; 2016 Mar; 22(5):1037-47. PubMed ID: 26933174
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Geyer H; Scherber R; Kosiorek H; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Maldonado N; Barosi G; Ferrari ML; Gale RP; Birgegard G; Xu Z; Zhang Y; Sun X; Xu J; Zhang P; te Boekhorst PA; Commandeur S; Schouten H; Pahl HL; Griesshammer M; Stegelmann F; Lehmann T; Senyak Z; Vannucchi AM; Passamonti F; Samuelsson J; Mesa RA
J Clin Oncol; 2016 Jan; 34(2):151-9. PubMed ID: 26598745
[TBL] [Abstract][Full Text] [Related]
20. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
Cerquozzi S; Tefferi A
Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
